Fierce Pharma
OCTOBER 1, 2024
Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)
MedCity News
OCTOBER 3, 2024
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 2, 2024
A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.
PharmaTech
OCTOBER 3, 2024
Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
OCTOBER 4, 2024
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.
MedCity News
SEPTEMBER 29, 2024
The Federal Trade Commission has sued CVS Caremark, Express Scripts and Optum Rx, alleging that they engage in “anticompetitive and unfair rebating practices” as it relates to insulin. One legal expert believes the FTC might win this legal battle. The post The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful? appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
SEPTEMBER 30, 2024
The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in emergency treatment for type I allergic reactions.
Fierce Pharma
OCTOBER 2, 2024
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.
MedCity News
OCTOBER 2, 2024
Alpine Physician Partners — which operates primary care organizations in several states — is implementing Ambience Healthcare’s documentation and coding tool after a successful pilot. Before adopting Ambience’s tool, Alpine clinicians spent 4.7 hours on charting per day, but now that time has dropped down to 1.2 hours per day. The post How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation appeared first on MedCity News.
pharmaphorum
OCTOBER 3, 2024
Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.
European Pharmaceutical Review
OCTOBER 4, 2024
A study has reported an approach for optimising metronidazole colonic delivery systems, to increase their potential efficacy when treating diverticulitis. Researchers developed intestinal colon-coated sustained-release matrix metronidazole tablets, using a Quality by Design (QbD) approach. Arévalo-Pérez et al. noted that metronidazole is a synthetic nitroimidazole and has activity against anaerobic bacteria.
Fierce Pharma
OCTOBER 3, 2024
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
MedCity News
OCTOBER 3, 2024
More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.
Pharmaceutical Technology
OCTOBER 2, 2024
Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new molecules at ELRIG 2024.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
OCTOBER 4, 2024
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
Fierce Pharma
OCTOBER 2, 2024
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.
MedCity News
OCTOBER 2, 2024
SCAN Health Plan and Astrana Health recently launched SCAN Allied, a Medicare Advantage plan designed for the Asian older adult population. It includes access to a network of culturally competent providers, specialists and pharmacies from Astrana Health. The post SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults appeared first on MedCity News.
pharmaphorum
OCTOBER 2, 2024
In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmaVoice
SEPTEMBER 30, 2024
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
Fierce Pharma
OCTOBER 2, 2024
Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31
MedCity News
OCTOBER 4, 2024
More than three-quarters of healthcare organizations reported paying more than $500,000 in ransom as a result of cyberattacks, according to a new report. The post Most Healthcare Organizations Have Paid $500K or More in Ransom Post-Cyberattack, Report Says appeared first on MedCity News.
Pharmatutor
SEPTEMBER 28, 2024
Importance of Pharmacovigilance practices currently in India and globally with the rising drug development processes across the world : An Update admin Sat, 09/28/2024 - 14:28 About Author Devansh Mehta, Founder Director, MarketMavericks Digital OPC PVT. LTD. And TRM Writer’s LLP, Meerut, Uttar Pradesh, India. Pin code: 250100.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Copyright Clearance Center
OCTOBER 1, 2024
October 1, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host “Let Licensing Bloom: The Root of Responsible AI” on 17 October, 3:00 – 4:00 pm CET at the 2024 Frankfurt Book Fair in Frankfurt Studio Hall 4.0, Room Europa. Panelists include Arend Kuester , CSIRO Publishing; Josh Jarrett , Wiley; Lui Simpson , Association of American Publishers (AAP); and Sarah Tegen , American Chemical Society (ACS).
Fierce Pharma
SEPTEMBER 30, 2024
After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. | Ahead of the CPHI conference in Milan, the events group has teased new research signaling an expected rebound for the CDMO industry—and a rejection of the BIOSECURE Act.
MedCity News
SEPTEMBER 29, 2024
What will happen in the fall remains to be seen, but the pledge is facilitating an open dialogue within the senior care industry about the problems it’s facing, along with some fresh thinking on potential solutions. The post The Harris Campaign is Right to Pledge More Resources For Senior Home Care, But the Devil Will Be in the Detail appeared first on MedCity News.
pharmaphorum
OCTOBER 4, 2024
FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
Pharmaceutical Technology
OCTOBER 3, 2024
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.
Fierce Pharma
OCTOBER 2, 2024
Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IR | New York District Judge John Cronan has rejected Amgen’s motion to dismiss an investor lawsuit—originally filed by a Michigan-based union pension fund—accusing the company of hiding a $10.7-billion tax bill from the public.
MedCity News
OCTOBER 2, 2024
Investing in nurses — by reimbursing them based on the value of their work — can improve job satisfaction thus reducing the churn rate and attracting more to the profession. The post Who Wins When Nurses Are Reimbursed for Care Delivery? appeared first on MedCity News.
pharmaphorum
OCTOBER 3, 2024
Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
339 
Let's personalize your content